Skip to main content
. Author manuscript; available in PMC: 2021 Feb 13.
Published in final edited form as: Schizophr Res. 2019 Jan 7;210:239–244. doi: 10.1016/j.schres.2018.12.028

Table 1:

Demographics and Clinical Measuresa

SZ (n= 61) HC (n= 31) t/X2 p value
Gender (% male) 72.1 70.96 0.014 .91
Age 27.84 (8.69) 28.58 (9.81) 0.372 .71
Parental Occupationb 7.18 (5.67) 5.84 (4.46) 14.911 .31
Smoking status (% smokers) 62.29 29.03 9.101 < .01
Diagnosis
  Schizophrenia 50
  Schizoaffective Disorder 8
  Schizophreniform Disorder 1
  Psychosis not otherwise specified 2
Prior antipsychotic treatment
  Antipsychotic naive 40
  Antipsychotic free interval (months)c 22.02 (43.33)
BPRSd
  Total
   Baseline 49.53 (9.95)
   Week 6e 31.67 (9.09)f
  Positive
   Baseline 14.60 (4.65)
   Week 6g 6.84 (2.93)h
  Negative
   Baseline 7.05 (3.13)
   Week 6g 5.76 (2.48)h
RBANSi
  Total index 71.14 (14.37) 90.29 (11.72) 6.337 < .01
  Immediate memory 77.52 (16.59) 95.65 (13.47) 5.203 < .01
  Visuospatial 72.38 (15.78) 82.97 (16.89) 2.925 < .01
  Language 83.52 (13.29) 97.06 (15.79) 4.254 < .01
  Attention span 79.32 (19.47) 96.10 (17.63) 3.976 < .01
  Delayed memory 73.32 (19.29) 92.71 (7.32) 6.702 < .01

SZ, schizophrenia; HC, healthy control

a

Mean (SD) unless indicated otherwise

b

Ranks determined from Diagnostic Interview for Genetic Studies (1 – 18 scale); higher rank (lower numerical value) corresponds to higher socioeconomic status

c

Antipsychotic free interval is denoted only for those with prior antipsychotic exposure (n= 20)

Brief Psychiatric Rating Scale (1 – 7 scale); positive (conceptual disorganization, hallucinatory behavior, and unusual thought content); negative (emotional withdrawal, motor retardation, and blunted affect)

d

n= 49

e

t= 13.352; p< .01

f

t= 11.030; p< .01

g

t= 3.515; p< .01

h

Repeatable Battery for the Assessment of Neuropsychological Status